Industry News

Pharmaceutical Industry News

AstraZeneca has fired another shot…

May 28th, 2026|Fierce Pharma|

AstraZeneca has fired another shot in its bladder cancer competition with Merck’s Keytruda, with the FDA clearing its PD-L1 inhibitor Imfinzi, used alongside standard of care, to become the first immunotherapy combination regimen for patients

The top pharmacy benefit manager…

May 28th, 2026|Fierce Pharma|

The top pharmacy benefit manager in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, allowing a significant number of patients to gain access to the drugs through their existing insurance.

As China-developed assets gain…

May 28th, 2026|Fierce Pharma|

As China-developed assets gain more attention from biopharma dealmakers, some industry watchers want to curb the trend before the U.S. loses key biotechnology capabilities. During these discussions, it was only fitting that Pfizer struck an

PharmaEssentia has hired Eric…

May 28th, 2026|Fierce Pharma|

PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization as it seeks to broaden the label of its rare blood cancer drug Besremi to a much wider market.

As AbbVie continues to capitalize…

May 27th, 2026|Fierce Pharma|

As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate Elahere, another of the acquired company’s clinical assets has crossed the FDA finish line.

In another round of Big Pharma…

May 27th, 2026|Fierce Pharma|

In another round of Big Pharma layoffs in New Jersey, Johnson & Johnson is dismissing 56 employees at its corporate headquarters in New Brunswick. The layoffs are part of the company's effort to separate its

With honor comes scrutiny….

May 27th, 2026|Fierce Pharma|

With honor comes scrutiny. Ivonescimab's plenary status means its Harmoni-6 results in first-line non-small cell lung cancer will be put under the microscope and critiqued carefully at the upcoming ASCO 2026 annual meeting.

As regulatory, pricing and policy…

May 27th, 2026|Fierce Pharma|

As regulatory, pricing and policy dynamics whipsaw in the United States, healthcare and life sciences firms are facing enormous pressures to keep profits rising, with those challenges now “becoming more acute by the quarter,” according

Italy’s antitrust agency, the…

May 27th, 2026|Fierce Pharma|

Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multiple sclerosis drug Tysabri (natalizumab).

Eli Lilly has successfully…

May 27th, 2026|Fierce Pharma|

Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the statement.

After a formal dispute resolution…

May 26th, 2026|Fierce Pharma|

After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness.